|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Barriers to mesalamine adherence in patients with inflammatory bowel disease:A qualitative analysis 显示文摘 | Devlen J Beusterien K Yen L | 2014 | J Manag Care Spec Pharm2014，20，3： | 1 |
| 2 | The effects of re-combinant human erythropoietin on functional health and well -being in chronic dialysis patients 显示文摘 | Beusterien KM’Nissenson AR Port FK | 1996 | J Am Soc Nephrol1996，7，5： | 1 |
| 3 | Barriers to e adherence in patients with inflammatory bowel disease: a qualitative analysis显示文摘 | Devlen J Beusterien K Yen L | 2014 | J Manag Care Spec Pharm2014，20，3： | 1 |
| 4 | The impact of pamidronate on inpatient and outpatient services among metastatic breast-cancer patients显示文摘 | Beusterien KN Hill MC Ackerman SJ | 2001 | Supportive Care In Cancer2001，9，3： | 1 |
| 5 | Barriers to mesalamine adherence in patients with inflammatory bowel disease:a qualitative analysis显示文摘 | Devlen J Beusterien K Yen L et a1 | 2014 | J Manag Care Spec Pharm2014，20，3： | 1 |
| 6 | Patient preferences for diabetic retinopathy health States显示文摘 | Szabo SM Beusterien KM Pleil AM | 2010 | Invest Ophthalmol Vis Sci2010，51，7： | 1 |
| 7 | Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized,open-label,cross-over trial:the boniva alendronate trial in osteoporosis (BALTO)显示文摘 | Emkey R Koltun W Beusterien K | 2005 | Curr Med Res Opin2005，21，12： | 1 |
| 8 | Health-related quality of life effects of modafinil for treatment of narcolepsy显示文摘 | Beusterien K Rogers AE Walsleben JA | 1999 | Sleep1999，22，6： | 1 |
| 9 | 改良偏头痛患者感受问卷的有效性:偏头痛急性治疗的满意度测量显示文摘Objective. -To evaluate the psychometric properties of the revised Patient Perception of Migraine Questionnaire (PPMQ-R), which measures satisfaction with migraine treatment. Background. -The original version of the PPMQ was developed prior to the introduction of newer migraine treatments, which may have attributes that influence treatment satisfaction. Methods. -Literature review, patient focus groups, and one-on-one patient interviews guided revisions to the original PPMQ. The revised questionnaire was tested in 200 migraine patients visiting neurologists and primary care clinics. At baseline, all subjects completed the PPMQ-R, a migraine-specific quality-of-life measure, and a migraine experience questionnaire; and 125 subjects completed assessments 24 hours after each migraine attack and within 30 days post-baseline. Factor analysis was performed to inform the development of a scoring algorithm, and reliability, validity, and responsiveness of the PPMQ-R were evaluated. Results. -Factor analyses confirmed that the revised questionnaire has five domains measuring satisfaction with efficacy, functionality, ease of use, medication cost, and bothersomeness of medication side effects. A total score can be created by taking the average of efficacy, functionality, and ease of use scores. The PPMQ-R scale scores and Total score demonstrated internal consistency reliability (Cronbach’s α: 0.80 to 0.98) and test-retest reliability (intra-class correlation coefficient: 0.79 to 0.91). Except for the Cost domain, the PPMQ-R scores discriminated among migraine pain severity levels (all P < .05) and levels of impairment in ability to work and perform usual activities (all P < .05). Except for the Ease of Use and Cost domains, mean PPMQ-R scores were significantly higher among patients with no change in treatment and whose pain improved between two consecutive migraine attacks (all P < .01). Conclusion. -The PPMQ-R is a reliable and valid measure of patient satisfaction with acute migraine treatment in women with frequent migraine attacks. | Revicki D. A. Kimel M. Beusterien K. 张殿增(译) | 2006 | 世界核心医学期刊文摘(神经病学分册)2006，2，9： | 1 |
| 10 | Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II—results显示文摘 | Michael Blute Stacey J Ackerman Alisoh L Rein Kathleen Beusterien Erin M Sullivan Craig P Tanio Michael J Strauss Michael J Manyak | 2000 | Urology2000，，6： | 1 |
| 11 | The effects of recombinant human erythropietin on functional health and well-being in chronic dialysis patients 显示文摘 | Beusterien KM Nissenson AR Port FK | 1996 | J Am Soc Nephrol1996，7，： | 1 |
| 12 | The effects of recombinant human erythropoietin on functional health and well - being in chronic dialysis patients显示文摘 | Beusterien KM Nissenson AR Port FK | 1996 | J Am Soc Nephrol1996，7，： | 1 |
| 13 | Patient preference for oncemonthly ibandronate versus once-weekly alendronate in a randomized,open-label,cross-over trial:the Boniva Alendronate Trial in Osteoporosis(BALTO)显示文摘 | Emkey R Koltun W Beusterien K | 2005 | Curt Meal Res'' Opin2005，21，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员